Natera
JoDee & Daniel’s story | Prospera™ For kidney transplant assessment
3:55
Natera
Meet Amanda, Colorectal Cancer Survivor & Signatera™ Patient
3:19
Natera
Meet Jon, Muscle-Invasive Bladder Cancer (MIBC) Survivor & Signatera™ Patient
3:25
Natera
Use of Signatera™ for MRD Surveillance in Stage I High-Grade Clear Cell Ovarian Carcinoma
6:18
Natera
Dr. James Duke’s Head & Neck Cancer Story
3:42
Natera
Kyle’s Colon Cancer Story
3:40
Natera
Meet Anj, Breast Cancer Survivor
3:20
Natera
Natera
1:56
Natera
Holly's Story | Clear Cell Ovarian Cancer Survivor & Signatera Patient
3:18
Natera
MRD in a Minute: Signatera™ Genome
0:47
Natera
MRD in a minute: John Sfakianos, MD
1:02
Natera
MRD in a Minute: Caroline Koffke, BSN, RN
1:01
Natera
Natera celebrates 10 years listed on the Nasdaq
2:46
Natera
MRD in a Minute: Saum Ghodoussipour, MD
1:06
Natera
MRD in a minute: Marcus Noel, MD
1:03
Natera
MRD in a minute: Changing how cancer is managed
2:00
Natera
How can a test help personalize cancer care?
1:20
Natera
MRD in a minute: Abstract overview Adanma Ayanambakkam, MD
3:06
Natera
Natera CEO Steve Chapman at Nasdaq
2:04
Natera
Natera CEO Steve Chapman on kidney genetics
1:58
Natera
Natera's Panorama & Horizon Test
3:04
Natera
Signatera™: A Personalized Test for Molecular Residual Disease Detection
1:20
Natera
Jason’s Story: Taking Control with MRD Testing
2:23
Natera
Fetal RhD NIPT | Natera
2:16
Natera
Brian's Story | Prospera Kidney
3:28
Natera
How Dr. Athreya uses a Prospera surveillance protocol for his kidney-pancreas recipients
21:55
Natera
How Dr. Hajjiri established Prospera protocols for patients w/ low & high immunological risk
17:09
Natera
How Professor Viklicky used Prospera to monitor treatment response in both ABMR and TCMR cases
25:37
Natera
Meet Danielle, breast cancer survivor and Signatera patient
2:57
Natera
Altera™ Comprehensive Genomic Profiling
1:24
Natera
Natera Oncology
1:26
Natera
How Dr. Anand’s experience in ProActive Study informed his center’s Prospera surveillance protocol
39:49
Natera
How Dr. Batarse diagnosed ABMR despite a negative biopsy from his routine Prospera protocol
29:50
Natera
Clinical Validation of a SNP-based Prenatal cfDNA Screening Test for Fetal RHD Status
6:47
Natera
Dr. Akkina & Dr. Coleman discuss the continuity of transplant recipient care w/surveillance protocol
35:31
Natera
Brent's Inspiring Bladder Cancer Journey | Natera Signatera Test
3:26
Natera
Dr. Millie Samaniego bridges the gap between study use & routine care by extending protocolized use
21:19
Natera
How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance
28:39
Natera
How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the CMS update
16:21
Natera
Natera Signatera Product Theater at SABCS 2022: The Cycle of ctDNA
1:46
Natera
Natera Signatera Product Theater at SABCS 2022: MRD
1:06
Natera
Natera Signatera Product Theater SABCS 2022: ctDNA Utility
0:41
Natera
Natera Signatera Product Theater at SABCS 2022: Example Case Report - Surveillance
1:21
Natera
Natera Signatera Product Theater at SABCS 2022: Exploratory Breast Lead Interval Study (EBLIS)
4:01
Natera
Natera Signatera Product Theater at SABCS 2022
27:03
Natera
How ctDNA can enhance patient care
1:03
Natera
ctDNA for Patients with Breast Cancer
2:01
Natera
Rachelle's Story
2:30
Natera
Vista general del tamizaje de portadores de Horizon
2:40
Natera
Vista general de la prueba de cáncer hereditario Empower
2:35
Natera
Empower Hereditary Cancer Test Overview
2:32
Natera
Vistara Single-Gene NIPT Overview
2:27
Natera
Vista general de la NIPT de un solo gen Vistara
2:35
Natera
Vista general de la prueba de aborto espontáneo Anora
2:21
Natera
Horizon Carrier Screening Overview
2:39
Natera
Vista general de la NIPT Panorama
2:26
Natera
Panorama NIPT Overview
2:16
Natera
Learn about SMA and the benefits of carrier screening through Lola’s story
2:18
Natera
Lynch Syndrome Short Take - Natera Academy Clinical Education
10:38
Natera
“Living with Lynch” - Four Women Share Their Cancer Previvor Journey
3:35
Natera
Clinical Review of Lynch Syndrome & Hereditary Cancer
9:33
Natera
Jennifer Plent's Story: Lynch Syndrome Cancer Previvor Advises to "Take Control of Your Health"
8:58
Natera
Elyse Azriel's Story: "Living with Lynch" - BRCA Testing is Not Enough
7:43
Natera
Natera is revolutionizing the standard of care with next-generation, cell-free DNA testing
1:56
Natera
Let's Talk about Miscarriage Instagram Live
20:16
Natera
Steven's Story: Long-term stable disease on immunotherapy
3:26
Natera
Don't believe the myths. You did not cause your miscarriage.
0:12
Natera
What is the Anora Miscarriage Test?
0:15
Natera
Anora Miscarriage Test Overview
2:23
Natera
Patient Perspective: Discovering Genetic Cancer Risk
2:31
Natera
Genetic Information Shifts a Breast Cancer Journey: Amy’s Story
2:54
Natera
Signatera para el control de la respuesta a la inmunoterapia
2:54
Natera
How Does Signatera for Immunotherapy Response Monitoring Work?
0:40
Natera
Signatera for immunotherapy response monitoring
2:22
Natera
Peace of mind powered by Signatera
3:12
Natera
World Congress of Melanoma 2021 Breakout Session
1:00:09
Natera
Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)
2:48
Natera
SignaCase: A Case Review: How being informed using Signatera helped Dan through his cancer journey
3:00
Natera
Breast Cancer Signatera Webinar
1:00:31
Natera
SignaCase: A Case Review: Unexplained Elevated CEA
4:36
Natera
Presentando Signatera, una prueba personalizada de sangre con informacion tumoral
0:45
Natera
Advances in testing: A personalized, ctDNA assay for MRD detection and surveillance
18:43
Natera
ESMO GI Clinical Forum: New customized tools for prediction of risk in CRC
15:49
Natera
Incorporating a Personalized, Tumor-informed ctDNA Monitoring Assay in Clinical Practice
49:25
Natera
A ctDNA assay for remote monitoring and risk stratification of CRC patients
35:05
Natera
Deep Dive Into the Utility of Personalized MRD Monitoring -- 2020 ASCO Recap
44:59
Natera
Introducing Signatera, a personalized, tumor-informed test
0:38
Natera
Introducing Signatera, a personalized, tumor-informed test
2:19
Natera
A ctDNA assay for remote monitoring and risk stratification
49:45
Natera
About Signatera and ctDNA
1:39
Natera
How can Signatera be incorporated in Clinical Trials
2:35
Natera
Natera's Corporate Mission and Vision
2:18
Natera
The Signatera Approach
2:27
Natera
Potential Clinical Applications of Signatera
2:11